This second study will compare the treatment of dexamethasone with Xerecept in patients already on low-dose steroid whose dose must be escalated to treat their symptoms.
In November 2005, NTI sold the worldwide exclusive rights to Xerecept to Celtic Pharma, and provides Celtic with contractual services surrounding the development of Xerecept.
“We feel that the existing treatment utilizing steroids provides an extra burden to this critically ill patient population,” said Paul Freiman, president and CEO of NTI. “We believe that Xerecept represents an alternative and hope to [give] these patients for a better quality of life.”